News and Announcements
Drivemycar Expands Fleet With 101 Subaru Impreza
- Published February 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- DriveMyCar significantly expands relationship with Subaru Australia
- Largest single expansion of DriveMyCar active fleet with over 20% increase
- Unique new marketing programme enables thousands of consumers to experience new model Subaru vehicles
- New product launched providing a unique marketing package for vehicle manufacturers
- Offering available in Sydney, Melbourne and Brisbane for private consumer renters and UberX drivers
- Material revenues expected to be earned by DriveMyCar
Collaborate Corporation Limited (ASX:CL8 or the Company) is pleased to announce that its DriveMyCar business unit will significantly expand its fleet size with the addition of 101 Subaru Impreza 2017 model vehicles in a further expansion of the existing relationship with Subaru (Aust) Pty Ltd. This is the largest ever addition to the DriveMyCar fleet and represents in excess of a 20% increase in the active fleet size. This expansion builds on the successful pilot deployment of ten Subaru Levorg wagons in October 2016.
In collaboration with Subaru, DriveMyCar has developed a unique marketing package that builds brand awareness for the new model Impreza and forms a core component of Subaru’s national marketing campaign for the 2017 model.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
